Birlasoft: Board Approves Q2 FY27 Results and Declares ₹3 Dividend

Birlasoft Limited’s Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company also declared an interim dividend of ₹3 per equity share, representing 150% of the face value of ₹2, for the financial year 2026-27. Additionally, the board approved the allotment of 1,00,997 equity shares under its incentive plans.

Financial Performance Review

At its meeting concluded on October 28, 2026, the Board of Directors of Birlasoft Limited has officially approved the unaudited standalone and consolidated financial results for the quarter and half-year period that ended on September 30, 2026. The detailed financial results, along with the limited review reports, have been attached to this disclosure. The company reported a robust financial performance, reflecting its continued growth trajectory.

Interim Dividend Declared

In a significant move for its shareholders, the Board of Directors has declared an interim dividend of ₹3 per equity share. This dividend corresponds to 150% of the face value of ₹2 per share. The dividend is for the financial year 2026-27 and is to be paid to the Members of the Company within 30 days from its declaration, in compliance with the Companies Act, 2013.

Equity Share Allotment

The Board also sanctioned the allotment of 1,00,997 equity shares of face value ₹2 each. These shares are intended for the Eligible Employees of Birlasoft Limited who have successfully exercised their Employee Stock Options under the company’s “Birlasoft Share Incentive Plan-2019” and “Birlasoft Share Incentive Plan-2022”. The newly allotted shares will rank pari-passu with the existing equity shares of the Company.

The paid-up capital of the Company has consequently increased to ₹55,95,36,106, comprising 27,97,68,053 equity shares with a face value of ₹2 each.

Source: BSE

Previous Article

Gujarat Toolroom Limited: CIRP Commenced, Public Announcement Made

Next Article

Sudeep Pharma: Reports Q2 FY27 Results with ₹5,181 Cr Profit